EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation
The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.
A lifetime of breakthroughs We were born to end patients’ suffering. To extend life and improve its quality. And right now, after decades...
Read more
pharma.be meets Nathalie Moll
EFPIA Director General talked with pharma.be about the Innovative Medicines Initiative, the main challenges facing the...
Read more
From Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers & Associations, Geneva,...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.